

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

Complete if Known

Application Number	10/010,645
Filing Date	November 13, 2001
First Named Inventor	Havenga et al.
Group Art Unit	1645 1636
Examiner Name	B. Whiteman M. Maruch
Attorney Docket Number	2578-5006.1US

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

Mymanich

Date
Considered

11/13/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08B(10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/010,645
		Filing Date	November 13, 2001
		First Named Inventor	Havenga et al.
		Group Art Unit	1645-1636
		Examiner Name	B. Whiteman M. Marich
Sheet 2 of 3	Attorney Docket Number	2578-5006 111S	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MM		CONGET, P.A., et al., "Adenoviral-mediated gene transfer into ex vivo expanded human bone marrow mesenchymal progenitor cells," 28 EXPERIMENTAL HEMATOLOGY 382-390 (2000).	
MM		GOOSSENS, P.H., et al., "Infection Efficiency of Type 5 Adenoviral Vectors in Synovial Tissue Can Be Enhanced With a Type 16 Fiber," 44(3) ARTHRITIS & RHEUMATISM 570-577 (March 2001).	
MM		HAVENGA, M.J.E., et al., "Exploiting the Natural Diversity in Adenovirus Tropism for Therapy and Prevention of Disease," 76(9) JOURNAL OF VIROLOGY 4612-4620 (May 2002).	
MM		HAVENGA, M.J.E., et al., "Improved Adenovirus Vectors for Infection of Cardiovascular Tissue," 75(7) JOURNAL OF VIROLOGY 3335-3342 (Apr. 2001).	
MM		MARX, J.C., et al., "High-Efficiency Transduction and Long-Term Gene Expression with a Murine Stem Cell Retroviral Vector Encoding the Green Fluorescent Protein in Human Marrow Stromal Cells," 10 HUMAN GENE THERAPY 1163-1173 (May 1, 1999).	
MM		OLMSTED-DAVIS, E.A., et al., "Use of a Chimeric Adenovirus Vector Enhances BMP2 Production and Bone Formation," 13 HUMAN GENE THERAPY 133-1347 (July 20, 2002).	
MM		ROELVINK, P.W., et al., "Identification of a Conserved Receptor-Binding Site on the Fiber Proteins of CAR-Recognizing Adenoviridae," 286 SCIENCE 1568-1571 (Nov. 1999).	
MM		ROELVINK, P.W., et al., "The Coxsackievirus-Adenovirus Receptor Protein Can Function as a Cellular Attachment Protein for Adenovirus Serotypes from Subgroups A, C, D, E, and F," 72(10) JOURNAL OF VIROLOGY 7909-7915 (Oct. 1998).	
MM		TURGEMAN, G., et al., "Bone Stem Cell Mediated Gene Therapy and Tissue Engineering," 15(7) JOURNAL OF BONE AND MINERAL RESEARCH S196 (Sept. 2000), Abstract.	
MM		TURGEMAN, G., et al., "Engineered human mesenchymal stem cells: a novel platform for skeletal cell mediated gene therapy," 3 J. GENE MED. 240-251 (2001).	
MM		VIGGESWARAPU, M., et al., "Adenoviral Delivery of LIM Mineralization Protein-1 Induces New-Bone Formation in Vitro and in Vivo," 83-A(3) THE JOURNAL OF BONE & JOINT SURGERY 364-376 (March 2001).	

Examiner Signature	<i>M. Marich</i>	Date Considered	11/13/03
--------------------	------------------	-----------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	«Patent Application No»
		Filing Date	«Patent Filing Date: July 4, 1996»
		First Named Inventor	«Inventor Short Form for Applicant»
		Group Art Unit	«Patent Group Art Unit» 1436
		Examiner Name	«Patent Examiner» Marwich
		Attorney Docket Number	«Matter Matter ID»
Sheet 3	of 3		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
mm		YOTNDA, P., et al., "Efficient infection of primitive hematopoietic stem cells by modified adenovirus," 8(12) GENE THERAPY 930-937 (June 2001).	
*		Partial European Search Report, European Application No. 01202619, dated May 7, 2002 (4 pages).	
*		International Search Report, International Application No. PCT/IL02/00443, dated July 24, 2002 (6 pages).	

Examiner Signature	M Marwich	Date Considered	11/13/01
--------------------	-----------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

+
* not a publication